Myeloid Suppressors in Inflammation

University of South Florida1 site in 1 country20 target enrollmentOctober 2010

ConditionsAsthma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Asthma
Sponsor: University of South Florida
Enrollment: 20
Locations: 1
Primary Endpoint: To identify and characterize specific cell types (human dendritic cells, myeloid-derived suppressor cells and T lymphocytes) that are present in acute and chronic asthma.
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Myeloid-derived suppressor cells (MDSC) have been studied for their ability to suppress T cell responses in vivo and in vitro. As a result, MDSC can regulate cellular responses to chronic inflammatory conditions such as cancer, leading to the induction of tolerance and, ultimately, tumor escape from immune surveillance.

Registry

clinicaltrials.gov

Start Date

October 2010

End Date

January 2012

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of South Florida

Responsible Party

Principal Investigator

Richard Lockey

principal investigator

University of South Florida

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Use of systemic corticosteroids within the previous two weeks.
•Pregnant and/or lactating females.
•Current tobacco use.
•Severe psychiatric illness.
•Current illicit substance abuse or dependence and/or abuse of alcohol.
•Current use of anti-microbial medications.
•Primary or secondary immunodeficiency.
•Any clinically significant uncontrolled medical condition that would put the patient's safety at risk.

Outcomes

Primary Outcomes

To identify and characterize specific cell types (human dendritic cells, myeloid-derived suppressor cells and T lymphocytes) that are present in acute and chronic asthma.

Time Frame: one year from start of study